Screening Unit

Main categories: Drug discovery

The screening unit offers academic researchers and industrial customers a broad range of services for identifying and optimising bioactive molecules for the drug discovery process. These include molecular modelling and in silico screening, development of screening assays and compound library screens, in vitro and in situ hit validation, hit optimisation and SAR analyses. A suite of cell and tissue-based disease models for oncology and neurological diseases are available for further validation of optimised hits or for independent phenotypic screens. High-throughput kinetic assays of changes in morphology or intracellular signalling over time may be integrated into chemical, genetic or optogenetic perturbation screens. A library of reporters in gene-delivery vectors are available for this purpose. The unit also has experience performing screens and toxicological evaluations in small animal models.

Contact details

High-throughput screens, screen-compatible assays, high-throughput microscopy, libraries, optogenetics, cell-based neurological disease models:
michael.courtney[at]utu.fi

3D oncology models, phenotypic screens, high-content screens:
malin.akerfelt[at]utu.fi

Medicinal chemistry, virtual screening and molecular modelling:
olli.pentikainen[at]utu.fi